Recent reports suggest that activating genomic alterations in KRAS, EGFR, and ALK, as well as loss of PTEN, possess the potential to biologically influence PD‐L1 expression in NSCLC.8, 11, 12, 13. This evidence concerns the gene EGFR and non-small cell lung carcinoma.